Weight Loss Drugs and Cardiovascular Risks
Author:
- 16 December 2010
- journal article
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 5 (2) , 138-144
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?Pharmacology Biochemistry and Behavior, 2010
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsNew England Journal of Medicine, 2010
- Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialThe Lancet, 2010
- Impact of Weight-Loss Medications on the Cardiovascular SystemAmerican Journal of Cardiovascular Drugs, 2007
- Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight LossCirculation, 2006
- The Efficacy and Safety of Sibutramine for Weight LossArchives of internal medicine (1960), 2004
- A Benefit-Risk Assessment of Sibutramine in the Management of ObesityDrug Safety, 2003
- Effect of sibutramine on weight maintenance after weight loss: a randomised trialThe Lancet, 2000
- Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in AdultsArchives of internal medicine (1960), 1998
- USE OF DRUGS IN THE TREATMENT OF OBESITYAnnual Review of Nutrition, 1997